This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Yutaka Takahashi, MD; Susan L. Tucker, PhD; Yasuhiko Kitadai, MD; Aaryan N. Koura, MD; Corazon D. Bucana, PhD; Karen R. Cleary, MD; Lee M. Ellis, MD

Arch Surg. 1997;132(5):541-546.

Abstract
Background
The value of these prognostic factors was compared with that of other clinicopathologic factors such as tumor grade, tumor stage, mucin production, vascular invasion, perineural invasion, and lymphatic invasion.

Objective
To determine whether the development of distant recurrence in patients with node-negative colon cancer could be predicted using vessel count and vascular endothelial growth factor (VEGF) expression.

Design
Paraffin-embedded colon cancers were immunostained for factor VIII, VEGF, basic fibroblast growth factor, and proliferating cell nuclear antigen; slides were reviewed for differentiation, mucin production, and the presence of vascular, lymphatic, and/or perineural invasion.

Setting
A large academic cancer referral center where 27 patients with node-negative colon cancer were operated on during 1988 and 1989.

Main Outcome Measure
The development of and interval to recurrence.

Results
Eight patients developed liver, lung, or lymph node metastases at a median of 24 months. The median follow-up for patients without cancer recurrence was 60 months. The mean tumor vessel count for those patients who remained disease-free was significantly fewer than for those patients who suffered a recurrence (20 vs 33, respectively). By univariate analysis, 3 factors—perineural invasion, vessel count, and VEGF expression—were correlated with time to recurrence. By multivariate analysis, only vessel count was significantly related to differences in time to recurrence. Expression of VEGF correlated with vessel count.

Conclusion
Vessel count and expression of VEGF may be useful for predicting distant recurrence in patients with node-negative colon cancer.

Arch Surg. 1997;132:541-546

Author Affiliations
From the Departments of Surgical Oncology (Drs Takahashi, Koura, and Ellis), Cell Biology (Drs Takahashi, Kitadai, Bucana, and Ellis), Biomathematics (Dr Tucker), and Pathology (Dr Cleary), University of Texas M. D. Anderson Cancer Center, Houston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma
Kaya et al.
J Bone Joint Surg Br 2009;91-B:784-788.
ABSTRACT | FULL TEXT  

Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress
Kopetz et al.
Cancer Res. 2009;69:3842-3849.
ABSTRACT | FULL TEXT  

Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer
Lurje et al.
Ann Oncol 2008;19:1734-1741.
ABSTRACT | FULL TEXT  

Optimal Pathologic Staging: Defining Stage II Disease
Compton
Clin. Cancer Res. 2007;13:6862s-6870s.
ABSTRACT | FULL TEXT  

The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer
Staton et al.
Gut 2007;56:1426-1432.
ABSTRACT | FULL TEXT  

Relationship between Expression of Vascular Endothelial Growth Factor in Tumor Tissue from Gastric Cancers and Chemotherapy Effects: Comparison between S-1 alone and the Combination of S-1 plus CDDP
Boku et al.
Jpn J Clin Oncol 2007;0:hym057v1-6.
ABSTRACT | FULL TEXT  

Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin
Boku et al.
Jpn J Clin Oncol 2007;0:hym015v1-7.
ABSTRACT | FULL TEXT  

When Does the Presence of the Target Predict Response to the Targeted Agent?
Bergsland
JCO 2006;24:213-216.
FULL TEXT  

Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal Cancer
Kuramochi et al.
Clin. Cancer Res. 2006;12:29-33.
ABSTRACT | FULL TEXT  

Tumour proliferation, angiogenesis, and ploidy status in human colon cancer
Cristi et al.
J. Clin. Pathol. 2005;58:1170-1174.
ABSTRACT | FULL TEXT  

Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma
Santini et al.
Ann Oncol 2005;16:1847-1848.
FULL TEXT  

Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial
Kabbinavar et al.
JCO 2005;23:3697-3705.
ABSTRACT | FULL TEXT  

In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models
Lee et al.
Clin. Cancer Res. 2005;11:3633-3641.
ABSTRACT | FULL TEXT  

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
Drevs et al.
Ann Oncol 2005;16:558-565.
ABSTRACT | FULL TEXT  

Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies
Gerber and Ferrara
Cancer Res. 2005;65:671-680.
ABSTRACT | FULL TEXT  

The Staging of Colorectal Cancer: 2004 and Beyond
Compton and Greene
CA Cancer J Clin 2004;54:295-308.
ABSTRACT | FULL TEXT  

Neuropilin-1 in Human Colon Cancer: Expression, Regulation, and Role in Induction of Angiogenesis
Parikh et al.
Am. J. Pathol. 2004;164:2139-2151.
ABSTRACT | FULL TEXT  

Antiangiogenic Therapy: More Promise and, Yet Again, More Questions
Ellis
JCO 2003;21:3897-3899.
FULL TEXT  

Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?
Graziano and Cascinu
Ann Oncol 2003;14:1026-1038.
ABSTRACT | FULL TEXT  

Vascular Endothelial Growth Factor Gene Expression in Colon Cancer Cells Exposed to Prostaglandin E2 Is Mediated by Hypoxia-inducible Factor 1
Fukuda et al.
Cancer Res. 2003;63:2330-2334.
ABSTRACT | FULL TEXT  

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
Kabbinavar et al.
JCO 2003;21:60-65.
ABSTRACT | FULL TEXT  

In Vivo Intracellular Signaling as a Marker of Antiangiogenic Activity
Solorzano et al.
Cancer Res. 2001;61:7048-7051.
ABSTRACT | FULL TEXT  

Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
Poon et al.
JCO 2001;19:1207-1225.
ABSTRACT | FULL TEXT  

Tumor Hypoxia, the Physiological Link between Trousseau's Syndrome (Carcinoma-induced Coagulopathy) and Metastasis
Denko and Giaccia
Cancer Res. 2001;61:795-798.
FULL TEXT  

Expression of Vascular Endothelial Growth Factor Can Predict Event-free Survival in Stage II Colon Cancer
Cascinu et al.
Clin. Cancer Res. 2000;6:2803-2807.
ABSTRACT | FULL TEXT  

Therapeutic Efficacy of the Suicide Gene Driven by the Promoter of Vascular Endothelial Growth Factor Gene against Hypoxic Tumor Cells
Koshikawa et al.
Cancer Res. 2000;60:2936-2941.
ABSTRACT | FULL TEXT  

Overexpression of CDC25B Phosphatase as a Novel Marker of Poor Prognosis of Human Colorectal Carcinoma
Takemasa et al.
Cancer Res. 2000;60:3043-3050.
ABSTRACT | FULL TEXT  

Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic Implications
Ellis et al.
The Oncologist 2000;5:11-15.
ABSTRACT | FULL TEXT  

Enhancement of Angiogenesis, Tumor Growth, and Metastasis by Transfection of Vascular Endothelial Growth Factor into LoVo Human Colon Cancer Cell Line
Kondo et al.
Clin. Cancer Res. 2000;6:622-630.
ABSTRACT | FULL TEXT  

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
Goldman et al.
Proc. Natl. Acad. Sci. USA 1998;95:8795-8800.
ABSTRACT | FULL TEXT  

Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src
Ellis et al.
J. Biol. Chem. 1998;273:1052-1057.
ABSTRACT | FULL TEXT